Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus.

Ferraro A, Buonocore SM, Auquier P, Nicolas I, Wallemacq H, Boutriau D, van der Most RG.

Hum Vaccin Immunother. 2019 May 31. doi: 10.1080/21645515.2019.1613126. [Epub ahead of print]

PMID:
31149870
2.

Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.

van den Berg RA, De Mot L, Leroux-Roels G, Bechtold V, Clement F, Coccia M, Jongert E, Evans TG, Gillard P, van der Most RG.

Front Immunol. 2018 Mar 26;9:564. doi: 10.3389/fimmu.2018.00564. eCollection 2018.

3.

Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.

Moris P, Jongert E, van der Most RG.

Hum Vaccin Immunother. 2018 Jan 2;14(1):17-27. doi: 10.1080/21645515.2017.1381809. Epub 2017 Dec 1. Review.

4.

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial.

van den Berg RA, Coccia M, Ballou WR, Kester KE, Ockenhouse CF, Vekemans J, Jongert E, Didierlaurent AM, van der Most RG.

Front Immunol. 2017 May 23;8:557. doi: 10.3389/fimmu.2017.00557. eCollection 2017.

5.

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.

van der Most RG, Clément F, Willekens J, Dewé W, Walravens K, Vaughn DW, Leroux-Roels G.

Clin Vaccine Immunol. 2017 Jun 5;24(6). pii: e00553-16. doi: 10.1128/CVI.00553-16. Print 2017 Jun.

6.

Seeking help: B cells adapting to flu variability.

van der Most RG, Roman FP, Innis B, Hanon E, Vaughn DW, Gillard P, Walravens K, Wettendorff M.

Sci Transl Med. 2014 Jul 23;6(246):246ps8. doi: 10.1126/scitranslmed.3008409.

PMID:
25101885
7.

Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies.

McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA.

Cancer Immunol Immunother. 2013 Mar;62(3):529-39. doi: 10.1007/s00262-012-1360-z. Epub 2012 Oct 16.

8.

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.

McCoy MJ, Lake RA, van der Most RG, Dick IM, Nowak AK.

Br J Cancer. 2012 Sep 25;107(7):1107-15. doi: 10.1038/bjc.2012.362. Epub 2012 Aug 21.

9.

Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates.

Lai CM, Estcourt MJ, Himbeck RP, Lee SY, Yew-San Yeo I, Luu C, Loh BK, Lee MW, Barathi A, Villano J, Ang CL, van der Most RG, Constable IJ, Dismuke D, Samulski RJ, Degli-Esposti MA, Rakoczy EP.

Gene Ther. 2012 Oct;19(10):999-1009. doi: 10.1038/gt.2011.169. Epub 2011 Nov 10.

PMID:
22071974
10.

Age-dependent differences in the pathogenesis of bovine respiratory syncytial virus infections related to the development of natural immunocompetence.

Antonis AF, de Jong MC, van der Poel WH, van der Most RG, Stockhofe-Zurwieden N, Kimman T, Schrijver RS.

J Gen Virol. 2010 Oct;91(Pt 10):2497-506. doi: 10.1099/vir.0.020842-0. Epub 2010 Jun 16.

PMID:
20554798
11.

Innate immunity defines the capacity of antiviral T cells to limit persistent infection.

Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, Fleming P, Tabarias H, Hill GR, van der Most RG, Scalzo AA, Smyth MJ, Degli-Esposti MA.

J Exp Med. 2010 Jun 7;207(6):1333-43. doi: 10.1084/jem.20091193. Epub 2010 May 31.

12.

Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.

Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, Freeman GJ, van der Most RG.

J Immunol. 2009 Dec 15;183(12):7898-908. doi: 10.4049/jimmunol.0901060.

13.

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.

van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, Scalzo AA, Degli-Esposti MA, Lake RA.

PLoS One. 2009 Sep 10;4(9):e6982. doi: 10.1371/journal.pone.0006982.

14.

Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.

Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW, Currie AJ.

J Immunol. 2009 May 1;182(9):5217-24. doi: 10.4049/jimmunol.0803826.

15.

Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection.

Blattman JN, Wherry EJ, Ha SJ, van der Most RG, Ahmed R.

J Virol. 2009 May;83(9):4386-94. doi: 10.1128/JVI.02524-08. Epub 2009 Feb 11.

16.

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy.

van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA.

Cancer Immunol Immunother. 2009 Aug;58(8):1219-28. doi: 10.1007/s00262-008-0628-9. Epub 2008 Dec 4.

PMID:
19052741
17.

Immunogenic anti-cancer chemotherapy as an emerging concept.

Haynes NM, van der Most RG, Lake RA, Smyth MJ.

Curr Opin Immunol. 2008 Oct;20(5):545-57. doi: 10.1016/j.coi.2008.05.008. Epub 2008 Jun 23. Review.

PMID:
18573339
18.

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R.

Immunity. 2008 May;28(5):710-22. doi: 10.1016/j.immuni.2008.02.020. Epub 2008 May 8.

19.

Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors.

Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW.

J Immunol. 2008 Feb 1;180(3):1535-44.

20.

Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.

van der Most RG, Currie AJ, Robinson BW, Lake RA.

Cell Death Differ. 2008 Jan;15(1):13-20. Epub 2007 Nov 16. Review.

21.

Identification of a CD4 T cell epitope in the pneumonia virus of mice glycoprotein and characterization of its role in protective immunity.

Claassen EA, van Bleek GM, Rychnavska ZS, de Groot RJ, Hensen EJ, Tijhaar EJ, van Eden W, van der Most RG.

Virology. 2007 Nov 10;368(1):17-25. Epub 2007 Jul 16.

22.

Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.

Antonis AF, van der Most RG, Suezer Y, Stockhofe-Zurwieden N, Daus F, Sutter G, Schrijver RS.

Vaccine. 2007 Jun 15;25(25):4818-27. Epub 2007 Apr 20.

PMID:
17499893
23.

A better way for a cancer cell to die.

Lake RA, van der Most RG.

N Engl J Med. 2006 Jun 8;354(23):2503-4. No abstract available.

PMID:
16760453
24.

Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice.

Lukens MV, Claassen EA, de Graaff PM, van Dijk ME, Hoogerhout P, Toebes M, Schumacher TN, van der Most RG, Kimpen JL, van Bleek GM.

Virology. 2006 Aug 15;352(1):157-68. Epub 2006 May 30.

25.

Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides.

van der Most RG, Himbeck R, Aarons S, Carter SJ, Larma I, Robinson C, Currie A, Lake RA.

J Immunother. 2006 Mar-Apr;29(2):134-42.

PMID:
16531814
26.

Gene therapy for malignant mesothelioma: beyond the infant years.

van der Most RG, Robinson BW, Nelson DJ.

Cancer Gene Ther. 2006 Oct;13(10):897-904. Epub 2006 Jan 27. Review.

PMID:
16439992
27.
28.

Kinetics of antiviral CD8 T cell responses during primary and post-vaccination secondary bovine respiratory syncytial virus infection.

Antonis AF, Claassen EA, Hensen EJ, de Groot RJ, de Groot-Mijnes JD, Schrijver RS, van der Most RG.

Vaccine. 2006 Mar 6;24(10):1551-61. Epub 2005 Oct 25.

PMID:
16310293
29.

Activation and inactivation of antiviral CD8 T cell responses during murine pneumovirus infection.

Claassen EA, van der Kant PA, Rychnavska ZS, van Bleek GM, Easton AJ, van der Most RG.

J Immunol. 2005 Nov 15;175(10):6597-604.

30.

Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.

Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BW, Lake RA.

Cancer Res. 2005 Sep 1;65(17):7580-4.

31.

Combining immunotherapy with chemotherapy to treat cancer.

van der Most RG, Robinson BW, Lake RA.

Discov Med. 2005 Jun;5(27):265-70.

32.

Fast track selection of immunogens for novel vaccines through visualisation of the early onset of the B-cell response.

Scibelli A, van der Most RG, Turkstra JA, Ariaans MP, Arkesteijn G, Hensen EJ, Meloen RH.

Vaccine. 2005 Mar 14;23(16):1900-9.

PMID:
15734062
33.

Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease.

de Groot-Mijnes JD, van Dun JM, van der Most RG, de Groot RJ.

J Virol. 2005 Jan;79(2):1036-44.

34.

Bovine respiratory syncytial virus infection influences the impact of alpha- and beta-integrin-mediated adhesion of peripheral blood neutrophils.

Soethout EC, Antonis AF, Ulfman LH, Hoek A, van der Most RG, Müller KE, Rutten VP.

Clin Exp Immunol. 2004 Dec;138(3):388-95. Erratum in: Clin Exp Immunol. 2005 Jan;139(1):165.

35.

HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells.

de Graaff PM, Heidema J, Poelen MC, van Dijk ME, Lukens MV, van Gestel SP, Reinders J, Rozemuller E, Tilanus M, Hoogerhout P, van Els CA, van der Most RG, Kimpen JL, van Bleek GM.

Virology. 2004 Sep 1;326(2):220-30.

36.

Three-color flow cytometry detection of virus-specific CD4+ and CD8+ T cells in the cat.

de Groot-Mijnes JD, van der Most RG, van Dun JM, te Lintelo EG, Schuurman NM, Egberink HF, de Groot RJ.

J Immunol Methods. 2004 Feb 1;285(1):41-54.

PMID:
14871533
37.

Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation.

van der Most RG, Murali-Krishna K, Lanier JG, Wherry EJ, Puglielli MT, Blattman JN, Sette A, Ahmed R.

Virology. 2003 Oct 10;315(1):93-102.

38.

Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis.

Antonis AF, Schrijver RS, Daus F, Steverink PJ, Stockhofe N, Hensen EJ, Langedijk JP, van der Most RG.

J Virol. 2003 Nov;77(22):12067-73.

39.

Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis.

van der Most RG, Murali-Krishna K, Ahmed R.

Int Immunol. 2003 Jan;15(1):119-25.

PMID:
12502732
40.

Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice.

van der Most RG, Harrington LE, Giuggio V, Mahar PL, Ahmed R.

Virology. 2002 Apr 25;296(1):117-24.

41.

In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb.

Puglielli MT, Zajac AJ, van der Most RG, Dzuris JL, Sette A, Altman JD, Ahmed R.

J Virol. 2001 Jun;75(11):5099-107.

42.
43.

Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein.

van der Most RG, Corver J, Strauss JH.

Virology. 1999 Dec 5;265(1):83-95.

44.

Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice.

van der Most RG, Murali-Krishna K, Whitton JL, Oseroff C, Alexander J, Southwood S, Sidney J, Chesnut RW, Sette A, Ahmed R.

Virology. 1998 Jan 5;240(1):158-67.

45.

Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice.

van der Most RG, Concepcion RJ, Oseroff C, Alexander J, Southwood S, Sidney J, Chesnut RW, Ahmed R, Sette A.

J Virol. 1997 Jul;71(7):5110-4.

46.

Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection.

van der Most RG, Sette A, Oseroff C, Alexander J, Murali-Krishna K, Lau LL, Southwood S, Sidney J, Chesnut RW, Matloubian M, Ahmed R.

J Immunol. 1996 Dec 15;157(12):5543-54.

PMID:
8955205
47.

Regulation of coronavirus mRNA transcription.

van Marle G, Luytjes W, van der Most RG, van der Straaten T, Spaan WJ.

J Virol. 1995 Dec;69(12):7851-6.

49.

Regulation of transcription of coronaviruses.

van Marle G, van der Most RG, van der Straaten T, Luytjes W, Spaan WJ.

Adv Exp Med Biol. 1995;380:507-10. Review.

PMID:
8830531

Supplemental Content

Loading ...
Support Center